Compare Bristol-Myers Squibb Co (BMY) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs PepsiCo, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while PepsiCo, Inc. trades at $135.76 (market cap $184.87B). The key difference: PepsiCo, Inc. is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | PEP | |
|---|---|---|
Market Cap | $116.30B | $184.87B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $170.44 |
52-Week Low | $42.60 | $133.81 |
Enterprise Value | $152.24B | $227.37B |
Dividend Yield | 4.42% | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
PepsiCo (PEP) trades at $138.49, up 0.81% with bearish technical signals but strong fundamentals. The company reported three consecutive quarterly earnings beats and maintains robust profitability with 10.78% net margin and 51.59% ROE. Recent news highlights price adjustments for snack products and sponsorship changes, while analysts maintain a consensus price target of $159.27 with 33% buy ratings.
PEP offers stable dividend income and operational strength but faces near-term technical pressure and competitive pricing challenges. The stock trades below analyst targets with upside potential, though investors should monitor North American performance trends and margin sustainability amid ongoing business transformation initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
